Eli Lilly Bolsters Drug Portfolio with Strategic Licensing Agreement
19.02.2026 - 12:03:04 | boerse-global.de
Pharmaceutical giant Eli Lilly & Co. has secured exclusive rights to a promising anti-inflammatory drug, marking another strategic move in its ongoing campaign to expand its development pipeline. The company has entered into a licensing agreement with Australia’s CSL Limited, paying an upfront sum of $100 million for the asset known as clazakizumab.
Under the terms of the exclusive license, Eli Lilly gains worldwide rights to develop and commercialize clazakizumab for all indications excluding end-stage kidney disease (ESKD). CSL retains exclusive rights to advance the drug specifically for the prevention of cardiovascular events in ESKD patients, an area where a Phase 3 trial (POSIBIL 6 ESKD) is already underway.
The Read more...
en | US5324571083 | ELI | boerse | 68593138 |
